Furosemide and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
Determining the interaction of Furosemide and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dasabuvir may increase the blood levels of furosemide. In some cases, this can increase the risk and/or severity of side effects such as dehydration, low blood pressure, electrolyte imbalance, ringing in the ear, hearing impairment, blood glucose elevations, and kidney problems. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know if you experience dry mouth, thirst, weakness, fatigue, drowsiness, dizziness, restlessness, muscle pains or cramps, decreased urination, irregular heartbeat, or gastrointestinal disturbances such as nausea and vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with ombitasvir/paritaprevir/ritonavir plus dasabuvir may increase the peak plasma concentration (Cmax) of furosemide. The mechanism of interaction has not been established. In 12 study subjects, administration of a single 20 mg dose of furosemide with once daily doses of ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg) plus twice daily doses of dasabuvir resulted in a 42% increase in mean Cmax of furosemide. The pharmacokinetics of ombitasvir, paritaprevir, ritonavir, and dasabuvir were not significantly altered.
MANAGEMENT: Clinical monitoring of patients is recommended during concomitant use of furosemide with ombitasvir, paritaprevir, ritonavir, and dasabuvir. Dosage adjustment may be required based on therapeutic response.
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir)." AbbVie US LLC, North Chicago, IL.
Generic Name: furosemide
Brand name: Lasix, Diaqua-2, Lo-Aqua
Synonyms: n.a.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Furosemide-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Furosemide-Omeclamox-Pak
- Furosemide-Omega-3 Fatty Acid Capsules
- Furosemide-Omega-3 Fatty Acids
- Furosemide-Omega-3 polyunsaturated fatty acids
- Furosemide-Omega-3-acid ethyl esters
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Furosemide Injection
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Furosemide Oral Solution
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Furosemide Tablets
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-FusePaq Fanatrex
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-FusePaq Synapryn
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-FusePaq Tabradol